Automatiqc® Medical Writing Technology

Innovative AI, cloud-based application to aid in quick and efficient document authoring

We appreciate the innovative spirit of MMS in enabling us to meet important milestones. Excellent job!
SVP, Research & Development
Biotechnology Sponsor

Free up resource time, improve quality, and bring efficiencies to the medical and regulatory writing process

Automatiqc® is a cloud-based solution that utilizes robotic process automation (RPA), a form of artificial intelligence (AI), to apply the required document formatting and style conventions. This frees up writers to focus on the key messaging, stakeholder alignment, and other key elements  that are most critical to the medical and regulatory writing process.

Additional key benefits of Automatiqc include:

  • Removes the burden of style and formatting from the regulatory or medical writer, saving time for critical data elements
  • Built-in set of rules that can be customized to meet any internal company or external audience document style requirements
  • Compounding efficiencies with document amendments, improving the quality of documents and reduces effort for the review and QC steps in subsequent drafts or document amendments
  • Complementary: processed documents are compatible with other tools, including PleaseReview, Veeva RIM and many others
  • Easy output provided in tracked changes for greater visibility to the writer

With this innovative medical writing technology, Automatiqc users are now able to focus where they can bring the greatest value – to the science of Medical & Regulatory Writing.

Get in touch to request a demo of Automatiqc!

Suggested For You

perspectives

October 8th, 2024

Diversity Action Plan Guidance Part I: Implications for Sponsors

webinar

October 22nd, 2024

Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules

perspectives

September 30th, 2024

Meet the Leaders Driving MMS’s European Growth

perspectives

September 30th, 2024

The Future of Data Management and Biostatistics: Trends and Technologies Shaping the Industry

perspectives

September 24th, 2024

Embracing Quality Management Maturity (QMM) at the Cornerstone of the Pharmaceutical Industry

perspectives

September 11th, 2024

From Historical Precedent to Modern Approvals: Lessons Learned on OTC Drug Products for FDA OMORs

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

perspectives

September 4th, 2024

Email Security – Navigating Through the Process of Validation and Compliance with Healthcare Business Stakeholders

perspectives

August 27th, 2024

Optimizing Oncology Drug Development: FDA Expedited Pathways, Real-Time Review, and Global Programs

regulatory intelligence

August 27th, 2024

Recent Guidance on Diversity Action Planning

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Take Reflections on the Recent Donanemab Approval